Mepolizumab response in patients with COPD and an eosinophilic phenotype with/without chronic bronchitis (CB): A METREX/METREO post hoc analysis - Vienna 2024

Emerging new clinical therapy for chronic obstructive pulmonary disease

Chair(s): Bernardino Alcazar Navarrete, Lies Lahousse

Session type: Poster session

Mepolizumab response in patients with COPD and an eosinophilic phenotype with/without chronic bronchitis (CB): A METREX/METREO post hoc analysis

Claus Vogelmeier

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Dupilumab responder types and predicting factors in patients with type 2 severe asthma: a real-world observational study

Lotte Bult

Poster

Abstract

Effect of Benralizumab treatment related immune modulation on COPD airway microbiome

Koirobi Haldar

Poster

Abstract

Exploring the Impact of Early Diagnosis and Treatment Initiation of Newly Diagnosed COPD Patients

Lorinc Polivka

Poster

Abstract

The iron(y) in COPD patients response to ICS: pharmacogenetic insights into the HISTORIC study

Charikleia Ntenti

Poster

Abstract

Mepolizumab response in patients with COPD and an eosinophilic phenotype with/without chronic bronchitis (CB): A METREX/METREO post hoc analysis

Claus Vogelmeier

Poster

Abstract

Vaccination status of the TRITRIAL study population.

Francesco Macagno

Poster

Abstract

Clinical trial design of biologic therapies in COPD: MATINEE study of mepolizumab

Ian Douglas Pavord

Poster

Abstract

The TRITRIAL study: CAT change sub-analysis according to number of COPD exacerbations.

Francesco Macagno

Poster

Abstract

Prospective study of association between step-up of inhaled maintenance therapy and CAT and mMRC scores in patients with stable COPD

Fen Dong

Poster

Abstract

Dupilumab efficacy and safety in patients with moderate-to-severe COPD with type 2 inflammation: pooled analysis of BOREAS and NOTUS

Surya Bhatt

Poster

Abstract

Dupilumab improves respiratory symptoms in patients with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial

Mona Bafadhel

Poster

Abstract

Dupilumab efficacy in patients with COPD and type 2 inflammation irrespective of mortality risk score

Claus Vogelmeier

Poster

Abstract

Prospective, non-interventional study to characterise use of triple therapy for COPD: TETRIS

Gernot G.u. Rohde

Poster

Abstract

Effect of 5 years of treatment with mucoactive drugs on COPD exacerbations in the Czech Republic: a real-life study

Jaromir Zatloukal

Poster

Abstract

Effects of one year treatment with extrafine fixed triple inhaled therapy in moderate COPD in a real-life setting results of the RATIONALE study

Andr S?di

Poster

Abstract

A Delphi Consensus Project to Capture Experts Opinion on the Position of Triple Therapies in COPD:Why, When and to Whom

Andriana Papaioannou

Poster

Abstract

Characteristics of patients with COPD treated with Budesonide/Glycopyrronium/Formoterol in the real world; The RECORD Study

Henrik Watz

Poster

Abstract

Dupilumab improves quality of life in non-exacerbators with moderate-to-severe COPD and type 2 inflammation: phase 3 BOREAS trial

Stephanie Christenson

Poster

Abstract

Dupilumab improves lung function in non-exacerbators with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial

Ashish Bansal

Poster

Abstract

Effectiveness of the cytoprotector ectoin in the treatment of patients with acute bronchitis

Sergii Zaikov

Poster

Abstract

CDN Connection Issue

The ERS Congress 2024, Vienna

#{title}